Zai Lab Limited

(NASDAQ:ZLAB)

Latest On Zai Lab Limited (ZLAB):

Date/Time Type Description Signal Details
2023-05-18 14:54 ESTNewsZai Lab gets priority review for lung cancer dug repotrectinib in ChinaN/A
2023-05-11 00:06 ESTNewsZai Lab Limited (ZLAB) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 21:59 ESTNewsZai Lab GAAP EPS of -$0.05 beats by $0.88, revenue of $62.79M misses by $2.68MN/A
2023-05-08 19:03 ESTNewsZai Lab Q1 2023 Earnings PreviewN/A
2023-04-27 13:44 ESTNewsZai Lab inks license deal with MediLink for potential cancer drugN/A
2023-03-20 07:26 ESTNewsKaruna/ Zai Lab succeed in late-stage trial for schizophrenia candidateN/A
2023-03-13 23:10 ESTNewsZai Lab Sees Profits On The Horizon As Commercialization AcceleratesN/A
2023-03-06 23:19 ESTNewsZai Lab: Positioned For Growth In The Oncology Treatment MarketN/A
2023-03-03 01:57 ESTNewsZai Lab Limited (ZLAB) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 11:05 ESTNewsZai Lab Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-01 20:40 ESTNewsZai Lab GAAP EPS of -$4.63 beats by $0.30, revenue of $215M misses by $1.4MN/A
2023-02-14 17:27 ESTNewsZai Lab Limited (ZLAB) Presents at Citi Biotech C-Suite Fireside Chat Series Conference (Transcript)N/A
2023-01-30 09:20 ESTNewsZai Lab's bacterial infection drug gets priority review in ChinaN/A
2023-01-18 14:40 ESTNewsParatek/ Zai Lab antibiotic added for reimbursement in ChinaN/A
2023-01-05 17:53 ESTNewsNovocure, Zai Lab surge as lung cancer therapy meets main goal in late-stage trialN/A
2023-01-05 17:52 ESTNewsWhy did NovoCure stock surge today? Phase 3 data for lung cancer candidateN/A
2022-12-16 15:05 ESTNewsChinese pharmas and biotechs risk of delisting averted as US regulators review auditsN/A
2022-12-13 17:07 ESTNewsZai Labs: Biopharma's Alibaba, But BetterN/A
2022-11-11 03:48 ESTNewsZai Lab Limited (ZLAB) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 17:42 ESTNewsZai Lab GAAP EPS of -$0.17 beats by $1.10, revenue of $57.5M beats by $3.77MN/A
2022-11-08 23:56 ESTNewsZai Lab appoints Zentalis' exec as chief scientific officerN/A
2022-11-08 23:56 ESTNewsZai Lab Q3 2022 Earnings PreviewN/A
2022-08-11 03:55 ESTNewsZai Lab Limited's (ZLAB) CEO Samantha Du on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 10:02 ESTNewsZai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04MN/A
2022-08-10 10:02 ESTNewsZai Lab Limited 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 15:25 ESTNewsZai Lab Q2 2022 Earnings PreviewN/A
2022-07-13 10:03 ESTNewsChina accepts Zai Lab's biologics license application for neuromuscular disorder drugN/A
2022-06-11 14:14 ESTNewsZai Lab drug gets 2 breakthrough therapy tags in China to treat lung cancer subtypeN/A
2022-06-03 12:39 ESTNewsNovocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trialN/A
2022-05-18 19:00 ESTNewsAs Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?N/A
2022-05-16 06:13 ESTNewsZai Lab Limited 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-11 16:09 ESTNewsZai Lab stock gains ~8% after Q1 earnings beat, strong product revenue growthN/A
2022-05-11 16:09 ESTNewsZai Lab Limited (ZLAB) CEO Samantha Du on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 19:50 ESTNewsZai Lab GAAP EPS of -$0.09 beats by $1.05, revenue of $46.72M beats by $1MN/A
2022-05-09 22:52 ESTNewsZai Lab Q1 2022 Earnings PreviewN/A
2022-04-29 00:40 ESTNewsTurning Point and Zai Lab fall after lung cancer data for repotrectinib in ChinaN/A
2022-03-22 11:59 ESTNewsZai Lab posts late-stage data for niraparib as maintenance therapy in ovarian cancerN/A
2022-03-16 20:43 ESTNewsU.S.-listed Chinese pharma stocks are on the riseN/A
2022-03-15 14:13 ESTNewsJosh Smiley to join Zai Lab as COON/A
2022-03-11 23:33 ESTNewsZai Lab, Beigene down amid potential violation of U.S. accounting regulations lawN/A
2022-03-11 04:45 ESTNewsZai Lab, Beigene down amid potential violation of foreign government ownership lawN/A
2022-03-09 17:32 ESTNewsZai Lab: Shares Are Cheap, But Not Without ReasonN/A
2022-03-09 00:30 ESTNewsZai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting LossesN/A
2022-03-03 05:16 ESTNewsZai Lab Limited (ZLAB) CEO Samantha Du on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-01 18:28 ESTNewsZai Lab GAAP EPS of -$7.58 misses by $0.73, revenue of $144.3M misses by $3.91MN/A
2022-03-01 00:34 ESTNewsZai Lab FY 2021 Earnings PreviewN/A
2022-02-18 06:26 ESTNewsZai Lab's repotrectinib for lung cancer subtype gets breakthrough therapy tag in ChinaN/A
2022-01-12 15:55 ESTNewsZai lab treats pancreatic cancer patient in China phase 3 trial of Tumor Treating FieldsN/A
2022-01-06 22:45 ESTNewsZai Lab's margetuximab application for HER2+ breast cancer accepted in ChinaN/A
2021-12-16 19:29 ESTNewsZai Lab's Nuzyra OK'd in China as Category 1 drug for pneumonia and skin infectionsN/A

About Zai Lab Limited (ZLAB):

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Quotes by TradingView

See Advanced Chart

General

  • Name Zai Lab Limited
  • Symbol ZLAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 1,194
  • Fiscal Year EndDecember
  • IPO Date2017-09-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.zailaboratory.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 227.95
  • Price/Book (Most Recent Quarter) 10.89
  • Enterprise Value Revenue 239.45
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.50
  • Next Year EPS Estimate -$2.31
  • Next Quarter EPS Estimate -$0.86
  • Operating Margin -616%
  • Return on Assets -23%
  • Return on Equity -37%
  • Revenue 48.96 million
  • Earnings Per Share -$3.12
  • Revenue Per Share $0.63
  • Gross Profit 32.22 million
  • Quarterly Earnings Growth 220.2%
View More

Highlights

  • Market Capitalization 11.91 billion
  • EBITDA -184450048
  • Analyst Target Price $174.24
  • Book Value Per Share $13.32
View More

Share Statistics

  • Shares Outstanding 88.02 million
  • Shares Float 70.76 million
  • % Held by Insiders 118%
  • % Held by Institutions 70.22%
  • Shares Short 1.46 million
  • Shares Short Prior Month 1.63 million
  • Short Ratio 3.79
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.14
  • 52 Week High $193.54
  • 52 Week Low $44.77
  • 50 Day Moving Average 159.3
  • 200 Day Moving Average 119.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Zai Lab Limited (ZLAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Zai Lab Limited (ZLAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2019-12-312020-03-19$4.65 million-$0.68-$0.60-14.23%
2019-09-302019-11-27$4.92 million-$1.03-$0.63-63.49%

Zai Lab Limited (ZLAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Zai Lab Limited (ZLAB) Chart:

Zai Lab Limited (ZLAB) News:

Below you will find a list of latest news for Zai Lab Limited (ZLAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Zai Lab Limited (ZLAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 01078.68TRUE00
2024-05-1750CALL0 0157.38TRUE00
2024-05-177.50CALL0 0341.18TRUE00
2024-05-17100CALL0 0267.78TRUE00
2024-05-1712.50CALL0 0119.41TRUE00
2024-05-17150.9CALL40 2876.27FALSE0.90
2024-05-1717.50.4CALL27 785.37FALSE0.40
2024-05-17200.33CALL0 2496.96FALSE00
2024-05-1722.51.15CALL0 10FALSE00
2024-05-17250.09CALL0 10FALSE00
2024-05-17300.05CALL0 10FALSE00
2024-05-17350CALL0 00FALSE00
2024-05-17400CALL0 00FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750PUT0 00FALSE00
2024-05-177.50PUT0 00FALSE00
2024-05-17100PUT0 00FALSE00
2024-05-1712.50PUT0 0111.43FALSE00
2024-05-17152.2PUT1 122112.99TRUE2.20
2024-05-1717.50PUT0 0131.91TRUE00
2024-05-17200PUT0 0151.69TRUE00
2024-05-1722.50PUT0 0190.5TRUE00
2024-05-17256.44PUT0 0201.48TRUE00
2024-05-17300PUT0 0242.81TRUE00
2024-05-17350PUT0 0237.91TRUE00
2024-05-17400PUT0 0261.47TRUE00
2024-06-212.50CALL0 0591.87TRUE00
2024-06-2150CALL0 0202.34TRUE00
2024-06-217.50CALL0 066.81TRUE00
2024-06-21107.3CALL0 1122.72TRUE00
2024-06-2112.50CALL0 088.85TRUE00
2024-06-211512.68CALL0 152.77FALSE00
2024-06-2117.50.8CALL0 7777.46FALSE00
2024-06-21200.63CALL0 18474.55FALSE00
2024-06-2122.50.17CALL0 23186.89FALSE00
2024-06-21250.6CALL0 1330FALSE00
2024-06-21300.06CALL0 90FALSE00
2024-06-21350.05CALL0 3330FALSE00
2024-06-21400.05CALL0 620FALSE00
2024-06-21450CALL0 00FALSE00
2024-06-21500CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00FALSE00
2024-06-217.50PUT0 00FALSE00
2024-06-21100PUT0 0131.76FALSE00
2024-06-2112.51.05PUT0 4999.04FALSE00
2024-06-21151.95PUT0 871.76TRUE00
2024-06-2117.53.6PUT0 1374.05TRUE00
2024-06-21205.6PUT0 18111.72TRUE00
2024-06-2122.57.2PUT0 2292.96TRUE00
2024-06-21259.4PUT0 103103.17TRUE00
2024-06-21306.3PUT0 0158.44TRUE00
2024-06-21359.2PUT0 0201.78TRUE00
2024-06-21400PUT0 0182.26TRUE00
2024-06-21450PUT0 0200.33TRUE00
2024-06-21500PUT0 0209.34TRUE00
2024-09-202.50CALL0 0457.94TRUE00
2024-09-2050CALL0 0285.2TRUE00
2024-09-207.50CALL0 0188.82TRUE00
2024-09-20100CALL0 091.76TRUE00
2024-09-2012.53.7CALL19 1076.09TRUE3.70
2024-09-20150CALL0 071.16FALSE00
2024-09-2017.53.4CALL0 267.25FALSE00
2024-09-20201.95CALL0 2081.97FALSE00
2024-09-2022.50.9CALL0 2070.43FALSE00
2024-09-20250.7CALL0 6782.57FALSE00
2024-09-20300CALL0 0106.96FALSE00
2024-09-20350.85CALL0 3087.66FALSE00
2024-09-202.50PUT0 00FALSE00
2024-09-2050PUT0 00FALSE00
2024-09-207.50PUT0 0136FALSE00
2024-09-20100PUT0 0100.48FALSE00
2024-09-2012.50PUT0 270.11FALSE00
2024-09-20152.55PUT0 1562.17TRUE00
2024-09-2017.54.1PUT0 467.14TRUE00
2024-09-20205.31PUT0 972.85TRUE00
2024-09-2022.53.7PUT0 8103.88TRUE00
2024-09-20258.4PUT0 199.74TRUE00
2024-09-203011.1PUT0 3114.14TRUE00
2024-09-20350PUT0 0124.86TRUE00
2024-12-202.50CALL0 0361.95TRUE00
2024-12-20515CALL0 1130.02TRUE00
2024-12-207.50CALL0 097.9TRUE00
2024-12-20109.74CALL0 573.4TRUE00
2024-12-2012.56.3CALL0 1378.5TRUE00
2024-12-20150CALL0 053.15FALSE00
2024-12-2017.53.45CALL0 1267.19FALSE00
2024-12-20202.39CALL0 1771.12FALSE00
2024-12-2022.53.3CALL0 1179.4FALSE00
2024-12-20251.85CALL0 4686.52FALSE00
2024-12-20300.65CALL0 2574.51FALSE00
2024-12-20350.76CALL0 5084.06FALSE00
2024-12-20400.9CALL0 888.46FALSE00
2024-12-20451.55CALL0 140FALSE00
2024-12-20500.33CALL2 787.79FALSE0.330
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 00FALSE00
2024-12-207.50PUT0 1124.32FALSE00
2024-12-20100PUT0 071.2FALSE00
2024-12-2012.50.8PUT0 267.85FALSE00
2024-12-20153.1PUT0 4366.08TRUE00
2024-12-2017.54.9PUT0 67671.13TRUE00
2024-12-20206PUT0 292669.14TRUE00
2024-12-2022.55PUT0 3287TRUE00
2024-12-20258.6PUT0 4970.62TRUE00
2024-12-20309PUT0 44377.98TRUE00
2024-12-203515.2PUT0 72785.05TRUE00
2024-12-204016.3PUT0 0123.18TRUE00
2024-12-20450PUT0 0132.16TRUE00
2024-12-20500PUT0 0132.98TRUE00
2025-01-172.50CALL0 098.68TRUE00
2025-01-1750CALL0 061.57TRUE00
2025-01-177.510.8CALL0 187.31TRUE00
2025-01-17100CALL0 067.1TRUE00
2025-01-1712.54.4CALL0 266.55TRUE00
2025-01-17153.3CALL0 163.42FALSE00
2025-01-1717.52.9CALL0 2364.78FALSE00
2025-01-17201.9CALL0 2167.55FALSE00
2025-01-1722.51.65CALL0 5568.92FALSE00
2025-01-17251.1CALL0 6976.65FALSE00
2025-01-17300.9CALL0 375.27FALSE00
2025-01-17350.9CALL0 39123.9FALSE00
2025-01-17400CALL0 093.65FALSE00
2025-01-172.50PUT0 00FALSE00
2025-01-1750PUT0 00FALSE00
2025-01-177.50PUT0 080.57FALSE00
2025-01-17101.2PUT0 50FALSE00
2025-01-1712.52.2PUT5 6670.74FALSE-0.05-0.02
2025-01-17153.2PUT0 30565.29TRUE00
2025-01-1717.54.4PUT0 1570.17TRUE00
2025-01-17200PUT0 070.69TRUE00
2025-01-1722.59PUT0 269.85TRUE00
2025-01-17250PUT0 093.47TRUE00
2025-01-17300PUT0 091.63TRUE00
2025-01-17350PUT0 093.19TRUE00
2025-01-17400PUT0 0102.81TRUE00

Latest ZLAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST27$25.23
Jun 13, 2022 7:59 PM EST100$25.23
Jun 13, 2022 7:59 PM EST49$25.18
Jun 13, 2022 7:59 PM EST6$25.18
Jun 13, 2022 7:59 PM EST100$25.18

Zai Lab Limited (ZLAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1704292/000156459020029580/0001564590-20-029580-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000031506619000812/0000315066-19-000812-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000031506620001289/0000315066-20-001289-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000090445419000247/0000904454-19-000247-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000090445420000196/0000904454-20-000196-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000090445420000552/0000904454-20-000552-index.htm
2019-05-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000092963819000531/0000929638-19-000531-index.htm
2020-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000092963820000139/0000929638-20-000139-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000095010319001958/0000950103-19-001958-index.htm
2019-03-29F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1704292/000095010319004111/0000950103-19-004111-index.htm
2019-05-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005677/0000950103-19-005677-index.htm
2019-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005712/0000950103-19-005712-index.htm
2019-05-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005714/0000950103-19-005714-index.htm
2019-05-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005786/0000950103-19-005786-index.htm
2019-05-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005917/0000950103-19-005917-index.htm
2019-05-06424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1704292/000095010319005999/0000950103-19-005999-index.htm
2020-01-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000095010320001096/0000950103-20-001096-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000095010320002781/0000950103-20-002781-index.htm
2020-09-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000104746920004887/0001047469-20-004887-index.htm
2020-09-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000104746920004959/0001047469-20-004959-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000110465920015242/0001104659-20-015242-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000110465920019426/0001104659-20-019426-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920104213/0001104659-20-104213-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920104219/0001104659-20-104219-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920105468/0001104659-20-105468-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920106975/0001104659-20-106975-index.htm
2020-09-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920107187/0001104659-20-107187-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920109116/0001104659-20-109116-index.htm
2020-10-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920113699/0001104659-20-113699-index.htm
2020-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000110465920116998/0001104659-20-116998-index.htm
2019-03-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000114420419015587/0001144204-19-015587-index.htm
2020-01-21POSASRPost-effective Amendment to an automatic shelf registration statementhttps://www.sec.gov/Archives/edgar/data/1704292/000119312520011149/0001193125-20-011149-index.htm
2020-01-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011154/0001193125-20-011154-index.htm
2020-01-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011159/0001193125-20-011159-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520011793/0001193125-20-011793-index.htm
2020-01-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000119312520012405/0001193125-20-012405-index.htm
2020-01-24424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1704292/000119312520013551/0001193125-20-013551-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1704292/000119312520037636/0001193125-20-037636-index.htm
2018-10-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018024170/0001564590-18-024170-index.htm
2018-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018024568/0001564590-18-024568-index.htm
2018-11-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018030310/0001564590-18-030310-index.htm
2018-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459018030832/0001564590-18-030832-index.htm
2019-03-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019006625/0001564590-19-006625-index.htm
2019-03-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019010185/0001564590-19-010185-index.htm
2019-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019021366/0001564590-19-021366-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019022165/0001564590-19-022165-index.htm
2019-06-2620-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019023549/0001564590-19-023549-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019024284/0001564590-19-024284-index.htm
2019-08-2320-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459019032910/0001564590-19-032910-index.htm
2019-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019033837/0001564590-19-033837-index.htm
2019-12-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459019046994/0001564590-19-046994-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020001004/0001564590-20-001004-index.htm
2020-01-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020001532/0001564590-20-001532-index.htm
2020-03-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020010986/0001564590-20-010986-index.htm
2020-03-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020011704/0001564590-20-011704-index.htm
2020-04-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020015797/0001564590-20-015797-index.htm
2020-04-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459020019745/0001564590-20-019745-index.htm
2020-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020024889/0001564590-20-024889-index.htm
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1704292/000156459020029580/0001564590-20-029580-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020031884/0001564590-20-031884-index.htm
2020-07-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020032675/0001564590-20-032675-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020039799/0001564590-20-039799-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020040369/0001564590-20-040369-index.htm
2020-09-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020042650/0001564590-20-042650-index.htm
2020-09-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1704292/000156459020043044/0001564590-20-043044-index.htm
2020-09-1820-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1704292/000156459020043994/0001564590-20-043994-index.htm
2019-09-12CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1704292/999999999719006805/9999999997-19-006805-index.htm